Clinical Trial Update: Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

View source ↗

Summary

A completed clinical trial evaluating salivary oxytocin as a biomarker in psychedelic-assisted psychotherapy for depression and anxiety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Major Depressive Disorder

Snippet

Sponsor: Tatiana Aboulafia Brakha | Conditions: Depression, Anxiety | Status: COMPLETED